OQROGet OQRO Pro
Insider trade

Eli Lilly (LLY)10% owner sold ~$8.35M

LILLY ENDOWMENT INC, 10% owner at Eli Lilly, sold ~$8.35M of Eli Lilly shares.

~$8.35M
Approx. value · 7,684 sh @ $1,086.75
92.2M
Holds after · shares reported
Traded
Jan 7, 2026
Filed
Jan 8, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Nov 10, 2025Insider · 1 personInsiders: 3 sales (~$16.4M)
  2. Nov 11, 2025Insider · 1 personInsiders: 27 sales (~$279.3M)
  3. Nov 12, 2025Insider · 1 personInsiders: 20 sales (~$308.4M)
  4. Nov 13, 2025Insider · 2 peopleInsiders: 3 sales (~$49.0M)
  5. Nov 14, 2025Insider · 1 personInsiders: 4 sales (~$183.8M)
  6. Nov 17, 2025Insider · 1 personInsiders: 2 sales (~$10.2M)
  7. Nov 18, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 18, 2025, the Board of Directors (the “Board”) of Eli Lilly and Company (the “Company”) elected Carolyn R. Bertozzi, Ph.D as a new member of the Board, effective December 8, 2025.”
  8. Nov 18, 2025Insider · 1 personInsiders: 10 sales (~$62.3M)
  9. Nov 19, 2025Insider · 1 personInsiders: 6 sales (~$176.1M)
  10. Nov 20, 2025FDAFDA drug approval: Retevmo
  11. Nov 20, 2025FDAFDA drug approval: Retevmo
  12. Nov 20, 2025Insider · 1 personInsiders: 5 sales (~$38.4M)
  13. Dec 19, 2025FDAFDA drug approval: Mounjaro

What came next

  1. Jan 23, 20265% stakeLILLY ENDOWMENT, INC. reported a passive stake (13G) of 9.8%
  2. Feb 4, 2026Company filing · Form 8-K · ResultsReported its results
  3. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  4. Apr 1, 2026FDAFDA drug approval: Foundayo
  5. Apr 20, 20265% stakeLILLY ENDOWMENT, INC. reported a passive stake (13G) of 9.7%
  6. Apr 30, 2026Company filing · Form 8-K · ResultsReported its results
  7. May 1, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 6.5%
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Eli Lilly

For Eli Lilly, OQRO holds 7 insider filings (SEC Form 4 or Form 144), 5 Congress trade reports, 189 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LLY page.

Other recent filings by LILLY ENDOWMENT INC, 10% owner

The full history of LILLY ENDOWMENT INC, 10% owner is on the profile page.

How this filing works

Other disclosures at Eli Lilly

Everything OQRO holds on this company is on its LLY page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data